Literature DB >> 16760439

Highlights and a hidden hazard--the FDA's new labeling regulations.

Jerry Avorn1, William Shrank.   

Abstract

Mesh：

Year:  2006        PMID： 16760439     DOI： 10.1056/NEJMp068119

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

2.  An Interactive User Interface for Drug Labeling to Improve Readability and Decision-Making.

Authors:  Hamed Abedtash; Jon D Duke
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

3.  Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration.

Authors:  Szymon Jarosławski; Pascal Auquier; Borislav Borissov; Claude Dussart; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2018-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.